PolarityTE adds Chris Nolet to the Board of Directors as Chair of its Audit Committee

– USA, UT –  PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced the appointment of Chris Nolet to its Board of Directors and as Chair of the Audit Committee.

“Chris’ experience is vast and not only includes his extensive work with Fortune 100 companies, but also substantial work with leading life science startups. I am confident that his deep industry expertise will make him an invaluable member of the PolarityTE Board of Directors,” said Peter Cohen, Board Chairman.

Mr. Nolet brings extensive audit and business experience with nearly forty years in the profession, most recently as the West Region Life Sciences Industry Leader and Partner at EY. Prior to EY, Mr. Nolet spent over twenty years at PricewaterhouseCoopers, where he was a partner and led the North America West Life Sciences Industry Group.

“Mr. Nolet brings a tremendous amount of life science operational experience and financial oversight to the PolarityTE Board of Directors,” said David Seaburg, CEO.

About Chris Nolet

In addition to Mr. Nolet’s role as the former lead for the West EY Life Sciences Industry Group, he was also a member of the Global EY Life Sciences Executive Leadership Group. Mr. Nolet is currently a member of the Board of Directors of two publicly traded biotechnology companies, Viela Bio and Revance Therapeutics. He is also a member of the Executive Committee and is Co-Chair of the Finance Committee of the California Life Sciences Industry Association. Mr. Nolet is a former member of the Finance & Investment Committee and Emerging Companies Section of the Biotechnology Innovation Organization, and he has testified before Congress with Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research, regarding the need for FDA reform.

“I have been very fortunate to work with the full range of life sciences companies and understand the underpinnings of what it takes to create a successful commercial biotech business,” said Mr. Nolet. “I am ecstatic to be part of the PolarityTE Board and look forward to drawing from my prior experience to make meaningful contributions to the PolarityTE team as we collectively pursue the mission of transforming the lives of patients through the application of our innovative regenerative tissue technology.”

Mr. Nolet holds a B.S. in Accounting from San Diego State University and is a Certified Public Accountant in California.

About PolarityTE

PolarityTE is focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures products from the patient’s own tissue and uses the patient’s own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to regenerate the target tissues. PolarityTE’s innovative method is intended to promote and accelerate the growth of the patient’s tissues to undergo a form of effective regenerative healing.

For more information: https://www.polarityte.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.